Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Salmerón J, Diago M, Andrade R, Pérez R, Solá R, Romero M, de la Mata M, Granados R, Ruiz-Extremera A, Muñoz de Rueda P. Salmerón J, et al. Among authors: de la mata m. J Viral Hepat. 2007 Feb;14(2):89-95. doi: 10.1111/j.1365-2893.2006.00771.x. J Viral Hepat. 2007. PMID: 17244248 Clinical Trial.
[Retrospective multicenter study of the efficacy of interferon alpha in chronic hepatitis C].
Salmerón J, Martín-Vivaldi R, Palacios A, Nogueras F, Aguilar J, de la Mata M, Andrade R, Puertas M, Sánchez H, Santalla F, Bellot V, Quintero D, Díaz F, Pérez Durán MA, Romero M, Luna JD, Ruiz-Extremera A. Salmerón J, et al. Among authors: de la mata m. Med Clin (Barc). 1996 Nov 23;107(18):689-92. Med Clin (Barc). 1996. PMID: 9082077 Spanish.
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Romero-Gómez M, et al. Among authors: de la mata m. Hepatology. 2009 Dec;50(6):1702-8. doi: 10.1002/hep.23206. Hepatology. 2009. PMID: 19845037 Clinical Trial.
Multicenter retrospective study of response to interferon in chronic hepatitis B.
Martín-Vivaldi R, Nogueras F, Vignote ML, Salmerón J, Aguilar J, Romero M, Andrade R, De la Mata M, Moreno JM, Pérez J, García G, López de Hierro M, Gómez F, Palacios A, Otero S, Suárez E, Poyatos A, Quintero D. Martín-Vivaldi R, et al. Among authors: de la mata m. Rev Esp Enferm Dig. 2000 Sep;92(9):561-72. Rev Esp Enferm Dig. 2000. PMID: 11138238 English, Spanish.
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Fernández Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernández I, Baliellas C, Carrión JA, de la Mata M, Buti M, Castells L, Albillos A, Romero M, Turnes J, Pons C, Moreno-Planas JM, Moreno-Palomares JJ, Fernández-Rodriguez C, García-Samaniego J, Prieto M, Fernández Bermejo M, Salmerón J, Badia E, Salcedo M, Herrero JI, Granados R, Blé M, Mariño Z, Calleja JL. Fernández Carrillo C, et al. Among authors: de la mata m. Hepatology. 2017 Jun;65(6):1810-1822. doi: 10.1002/hep.29097. Epub 2017 Apr 28. Hepatology. 2017. PMID: 28170112
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C.
Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M. Ampuero J, et al. Among authors: de la mata m. J Hepatol. 2018 May;68(5):940-948. doi: 10.1016/j.jhep.2017.12.019. Epub 2017 Dec 28. J Hepatol. 2018. PMID: 29288753
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators. Sulkowski MS, et al. Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096. Epub 2013 Feb 11. Hepatology. 2013. PMID: 23081753 Clinical Trial.
Boceprevir for untreated chronic HCV genotype 1 infection.
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Poordad F, et al. N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494. N Engl J Med. 2011. PMID: 21449783 Free PMC article. Clinical Trial.
283 results